Is biopharma’s first $1.5M therapy now in Phase III? – Endpoints News
Endpoints News |
Is biopharma’s first $1.5M therapy now in Phase III?
Endpoints News Keying off of Spark Therapeutics’ rollout of Luxturna as the first approved gene therapy in the US, the analysts at Leerink have been crunching the numbers on what the first hemophilia gene therapies could fetch. And by raising their estimate to $1.5 … |
Genetic Literacy Project |
Can CRISPR and gene editing save our ‘devastated’ coral reefs?
Genetic Literacy Project But some researchers are hoping new gene-editing tools like CRISPR – Cas9 may provide new insights and perhaps even the means to save corals from becoming the wreckage of a warming world. A new study led by researchers at the Stanford University School … |
Business Insider |
Indication-based pricing for Novartis’ CAR-T cell therapy Kymriah …
Business Insider A cutting-edge new cancer treatment just got approved to treat more people with certain blood cancers last week. The second approval came with a different price. Controlling CAR-T: How scientists plan to make the engineered T …Chemical & Engineering News Kymriah Gets Expanded Approval for Large B-Cell LymphomaSPT Industry Guide |